209984-56-5

Basic information

• Product Name: DIBENZAZEPINE
• Synonyms: DIBENZAZEPINE;N-[(1S)-2-[[(7S)-6,7-Dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluorobenzeneacetamide;Dibenzazepine (Deshydroxy LY 411575);γ-Secretase Inhibitor XX;YO-01027/Dibenzazepine/LY 411575;(2S)-2-[2-(3,5-Difluorophenyl)acetaMide]-N-[(7S)-5-Methyl-6-oxo-6,7-dihydro-5H-dibenzo[B,D]azepin-7-;(S)-2-(2-(3,5-Difluorophenyl)acetamido)-N-((S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7;YO-01027 (Dibenzazepine)
• CAS NO: 209984-56-5
• Molecular Formula: C₂₆H₂₃F₂N₃O₃
• Molecular Weight: 463.49
• Product Categories: All Inhibitors;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;A dipeptidic (c)-secretase inhibitor and anti-Alzheimer agent.;Inhibitor
• Mol File: 209984-56-5.mol
• Article Data: 1

Chemical Properties

• Melting Point: 257-259?C
• Boiling Point: 801.334°C at 760 mmHg
• Flash Point: 438.431°C
• Appearance: white to beige/
• Density: 1.35
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.637
• Storage Temp.: -20°C Freezer
• Solubility: DMSO: soluble15mg/mL, clear
• PKA: 12.76±0.20(Predicted)
• CAS DataBase Reference: DIBENZAZEPINE(CAS DataBase Reference)
• NIST Chemistry Reference: DIBENZAZEPINE(209984-56-5)
• EPA Substance Registry System: DIBENZAZEPINE(209984-56-5)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26
• WGK Germany: 3
• Hazardous Substances Data: 209984-56-5(Hazardous Substances Data)

Usage

Description

DIBENZAZEPINE, also known as DBZ, is a cell-permeable, potent γ-secretase inhibitor that significantly lowers both brain and plasma Aβ40 levels. It is a dipeptidic compound with a white solid appearance, playing a crucial role in the treatment of Alzheimer's disease by inhibiting the proteolysis of amyloid precursor protein (APP) and other type 1 transmembrane proteins.

Uses

Used in Pharmaceutical Industry:
DIBENZAZEPINE is used as an anti-Alzheimer agent for its ability to reduce Aβ40 levels by 71% within 4 hours after a single 100 μM/kg dose in an APP transgenic mouse model. It potently blocks the cleavage of Notch into its active signaling effector, Notch intracellular domain, in human T cell lymphoma (SupT1) cells (IC50 = 1.7 nM), thus demonstrating its effectiveness in treating Alzheimer's disease.
Used in Research and Development:
DIBENZAZEPINE is used as a dipeptidic γ-secretase inhibitor in research and development for its potential to inhibit Notch processing and induce conversion of proliferative crypt cells to post-mitotic goblet cells in mouse models. This application aids in understanding the compound's effects on cellular processes and its potential therapeutic applications.

Biochem/physiol Actions

Cell permeable: yes

InChI:InChI=1/C26H23F2N3O3/c1-15(29-23(32)13-16-11-17(27)14-18(28)12-16)25(33)30-24-21-9-4-3-7-19(21)20-8-5-6-10-22(20)31(2)26(24)34/h3-12,14-15,24H,13H2,1-2H3,(H,29,32)(H,30,33)/t15-,24-/m0/s1

Upstream product

• 209984-32-7 7-amino-5-methyl-5H-dibenzo[b,d]azepin-6(7H)-one hydrochloride 
• 208124-34-9 N-(3,5-Difluorophenylacetyl)-L-alanine 

Relevant articles and documents

CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS

Disclosed are compounds which inhibit beta -amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits beta -amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.